|
1
|
Wang Y, Xu Z, Zhou F, Sun Y, Chen J, Li L,
Jin H and Qian Q: The combination of dendritic cells-cytotoxic T
lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts
immune and clinical responses in patients with malignant tumors.
Exp Hematol Oncol. 4:322015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ouyang Z, Wu H, Li L, Luo Y, Li X and
Huang G: Regulatory T cells in the immunotherapy of melanoma.
Tumour Biol. 37:77–85. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brower V: Combination immunotherapy
breakthrough for melanoma. Lancet Oncol. 16:e3182015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brower V: Immunotherapy combination
promising for melanomas. Lancet Oncol. 16:e2652015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Boon T, Coulie PG, Van den Eynde BJ, van
der Bruggen P and Human T: cell responses against melanoma. Annual
Rev Immunol. 24:175–208. 2006. View Article : Google Scholar
|
|
6
|
Garbe C, Eigentler TK, Keilholz U,
Hauschild A and Kirkwood JM: Systematic review of medical treatment
in melanoma: Current status and future prospects. Oncologist.
16:5–24. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fourcade J and Zarour HM: Strategies to
reverse melanoma-induced T-cell dysfunction. Clin Dermatol.
31:251–256. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen R, Deng X, Wu H, Peng P, Wen B and Li
F and Li F: Combined immunotherapy with dendritic cells and
cytokine-induced killer cells for malignant tumors: A systematic
review and meta-analysis. Int Immunopharmacol. 22:451–464. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
El Ansary M, Mogawer S, Elhamid SA,
Alwakil S, Aboelkasem F, Sabaawy HE and Abdelhalim O: Immunotherapy
by autologous dendritic cell vaccine in patients with advanced HCC.
J Cancer Res Clin Oncol. 139:39–48. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang S and Wang Z: Efficacy and safety of
dendritic cells co-cultured with cytokine-induced killer cells
immunotherapy for non-small-cell lung cancer. Int Immunopharmacol.
28:22–28. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dougan M and Dranoff G: Immune therapy for
cancer. Annu Rev Immunol. 27:83–117. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin T, Song C, Chuo DY, Zhang H and Zhao
J: Clinical effects of autologous dendritic cells combined with
cytokine-induced killer cells followed by chemotherapy in treating
patients with advanced colorectal cancer: A prospective study.
Tumour Biol. 37:4367–4372. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu X, Zhao H, Liu L, Cao S, Ren B, Zhang
N, An X, Yu J, Li H and Ren X: A randomized phase II study of
autologous cytokine-induced killer cells in treatment of
hepatocellular carcinoma. J Clin Immunol. 34:194–203. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Banchereau J and Steinman RM: Dendritic
cells and the control of immunity. Nature. 392:245–252. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tan G, Zhang X, Feng H, Luo H and Wang Z:
The therapeutic effect of cytokine-induced killer cells on
pancreatic cancer enhanced by dendritic cells pulsed with K-ras
mutant peptide. Clin Dev Immunol. 2011:6493592011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wayteck L, Breckpot K, Demeester J, De
Smedt SC and Raemdonck K: A personalized view on cancer
immunotherapy. Cancer Lett. 352:113–125. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Olioso P, Giancola R, Di Riti M, Contento
A, Accorsi P and Iacone A: Immunotherapy with cytokine induced
killer cells in solid and hematopoietic tumours: A pilot clinical
trial. Hematol Oncol. 27:130–139. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume
KG and Weissman IL: Use of a SCID mouse/human lymphoma model to
evaluate cytokine-induced killer cells with potent antitumor cell
activity. J Exp Med. 174:139–149. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pan Y, Tao Q, Wang H, Xiong S, Zhang R,
Chen T, Tao L and Zhai Z: Dendritic cells decreased the concomitant
expanded Tregs and Tregs related IL-35 in cytokine-induced killer
cells and increased their cytotoxicity against leukemia cells. PLoS
One. 9:e935912014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jäkel CE and Schmidt-Wolf IG: An update on
new adoptive immunotherapy strategies for solid tumors with
cytokine-induced killer cells. Expert Opin Biol Ther. 14:905–916.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chávez-Galán L, Arenas-Del Angel MC,
Zenteno E, Chávez R and Lascurain R: Cell death mechanisms induced
by cytotoxic lymphocytes. Cell Mol Immunol. 6:15–25. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hishii M, Kurnick JT, Ramirez-Montagut T
and Pandolfi F: Studies of the mechanism of cytolysis by
tumour-infiltrating lymphocytes. Clin Exp Immunol. 116:388–394.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Franceschetti M, Pievani A, Borleri G,
Vago L, Fleischhauer K, Golay J and Introna M: Cytokine-induced
killer cells are terminally differentiated activated CD8 cytotoxic
T-EMRA lymphocytes. Exp Hematol. 37:616–628.e2. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wongkajornsilp A, Wamanuttajinda V,
Kasetsinsombat K, Duangsa-ard S, Sa-ngiamsuntorn K, Hongeng S and
Maneechotesuwan K: Sunitinib indirectly enhanced anti-tumor
cytotoxicity of cytokine-induced killer cells and CD3+CD56+ subset
through the co-culturing dendritic cells. PLoS One. 8:e789802013.
View Article : Google Scholar : PubMed/NCBI
|
